U.S. market Closed. Opens in 17 hours 11 minutes

TXG | 10x Genomics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 21.30 - 22.46
52 Week Range 15.28 - 57.90
Beta 2.09
Implied Volatility 58.64%
IV Rank 30.73%
Day's Volume 952,828
Average Volume 1,837,195
Shares Outstanding 120,491,423
Market Cap 2,592,975,423
Sector Healthcare
Industry Medical - Healthcare Information Services
IPO Date 2019-09-12
Valuation
Profitability
Growth
Health
P/E Ratio -10.60
Forward P/E Ratio N/A
EPS -2.03
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 1,259
Country USA
Website TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
TXG's peers: AMWL, DOCS, GDRX, PGNY, SDGR, TDOC, TWST, FATE, BEAM, VCYT, GH, VEEV, GEHC
*Chart delayed
Analyzing fundamentals for TXG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see TXG Fundamentals page.

Watching at TXG technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TXG Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙